H2O2 production by whole blood PMNs from controls and patients
| Subjects . | MFI of DCF content . | |||
|---|---|---|---|---|
| PBS . | TNF . | fMLP . | TNF + fMLP . | |
| African controls (n = 11) | 14.4 ± 0.9 | 18.2 ± 2 | 24.9 ± 1.6 | 62.6 ± 6.5 |
| Non-VOC group (n = 15) | 23.1 ± 2.94-150 | 28.6 ± 3.94-150 | 30.6 ± 3.4 | 62.5 ± 8.7 |
| VOC group (n = 17) | 27.5 ± 3.54-150 | 33.6 ± 4.14-150 | 40.5 ± 5.54-150 | 92.0 ± 7.14-150,4-151,‡ |
| HU group (n = 9) | 19.7 ± 2.5 | 23.4 ± 3.6 | 31.5 ± 7.7 | 51.1 ± 7.2 |
| Subjects . | MFI of DCF content . | |||
|---|---|---|---|---|
| PBS . | TNF . | fMLP . | TNF + fMLP . | |
| African controls (n = 11) | 14.4 ± 0.9 | 18.2 ± 2 | 24.9 ± 1.6 | 62.6 ± 6.5 |
| Non-VOC group (n = 15) | 23.1 ± 2.94-150 | 28.6 ± 3.94-150 | 30.6 ± 3.4 | 62.5 ± 8.7 |
| VOC group (n = 17) | 27.5 ± 3.54-150 | 33.6 ± 4.14-150 | 40.5 ± 5.54-150 | 92.0 ± 7.14-150,4-151,‡ |
| HU group (n = 9) | 19.7 ± 2.5 | 23.4 ± 3.6 | 31.5 ± 7.7 | 51.1 ± 7.2 |
After preincubation with DCFH-DA (100 μM) for 15 minutes at 37°C, whole blood was pretreated with PBS or TNF (100 U/mL) for 30 minutes and then treated with PBS or fMLP at 10−6 M for 5 minutes. The MFI of DCF was recorded as described in “Patients, materials, and methods.” Values are given as means ± SEM.
Significantly different from controls (P < .05).
Significantly different from the non-VOC group (P < .05).
Significantly different from the HU-treated group (P < .05).